SAN DIEGO, CA / ACCESS Newswire / May 2, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ
ANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
